The Efficacy of Phosphatidylserine-Omega3 in Elderly Subjects With Memory Impairment
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00736034|
Recruitment Status : Completed
First Posted : August 15, 2008
Results First Posted : March 24, 2010
Last Update Posted : March 30, 2010
The primary objective of this trial is to assess the ability of Phosphatidylserine-Omega3 to improve cognitive performance in elderly subjects with memory impairment.
This study is a single-center, open-label 15 weeks duration trial to assess efficacy of Phosphatidylserine-Omega3 in elderly subjects with memory impairment.
|Condition or disease||Intervention/treatment||Phase|
|Memory Impairment||Dietary Supplement: Phosphatidylserine-Omega3 (SharpPS™-Gold)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||18 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Single-Center, Open-Label Study to Assess the Efficacy of SharpPS™-Gold in Elderly Subjects With Memory Impairment|
|Study Start Date :||September 2008|
|Primary Completion Date :||March 2009|
|Study Completion Date :||April 2009|
Dietary Supplement: Phosphatidylserine-Omega3 (SharpPS™-Gold)
- Change From Baseline in Neuropsychological Computerized Test [ Time Frame: baseline, 15 weeks ]The computerized neuropsychological assessment software consists of seven separate tasks: symbol spotting, pattern identification, pattern recall, digit-symbol substitution, digits span forward, digits span backward and delayed pattern recall. Based on the results obtained in the single tasks, eight cognitive composite scores are calculated including focused attention, sustained attention, memory recognition & recall, visuospatial learning, spatial short term memory, executive functions and mental flexibility.The total score range is from 0 to 100 points(0 is worse, 100 is best).
- Clinical Global Impression of Change (CGI-C)Scale [ Time Frame: 15 weeks ]The Clinical Global Impression of Change (CGI-C)scale is designed to record the clinician's global impression of change. Global improvement score ranges from 1 = "Very much improved", through 4 = "No change", to 7 = "Very much worse". Participants who experienced an improvement (scores 1, 2 or 3) were classified as improved over the treatment period.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00736034
|The Tel Aviv Sourasky Medical Center, Neurology department|
|Tel Aviv, Israel, 64239|
|Principal Investigator:||Veronica Vakhapova, MD||Sourasky Medical Center|